Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ampio demonstrates impact of Danazol in allergic rhinitis treatment
Danazol is a weak androgen approved at high doses for the treatment of endometriosis, fibrocystic disease of the breast and hereditary angioedema. The study was intended to evaluate
Danazol is a weak androgen approved at high doses for the treatment of endometriosis, fibrocystic disease of the breast and hereditary angioedema. The study was intended to evaluate
The companies will lay emphasis on developing and commercializing three drug candidates, including two of Miragen’s programs (miR-208 and miR-15/195) and one additional target which is to be
Following the deal, 51% of the JVC will be owned by Materia Medica and 49% by Angel Biotechnology. The companies intend to commission new product programmes, manage production
TAK-875 is a selective agonist of GPR40, one of the G-protein-coupled receptors that are expressed in pancreatic islet cells. The first double-blind, randomized, 24-week Phase 3 trial in
The G4 platform provides an intuitive user interface across the products and a single unified database across automated medication dispensing cabinets which aid in decreasing the risk of
The proteomic technology will be applied to biomarker discovery, target discovery and validation, and companion diagnostics. SomaLogic CEO Larry Gold said their technology would help address the issues
The infections include Complicated Intra-Abdominal Infections (cIAI) and Complicated Urinary Tract Infections (cUTI). CAZ-AVI comprises cephalosporin (ceftazidime) and a novel beta-lactamase inhibitor (avibactam), which helps overcome antibiotic-resistance and
PromoMats will enable life sciences companies to manage promotional material life cycle including concept and strategy, association of claims and reference documents, besides medical, legal and regulatory review.
MGCD290 is an oral Hos2 fungal inhibitor and was designed to be co-administered with azoles like fluconazole in order to enhance activity against fungal infections. The Phase 2
UshStat utilizes the company’s LentiVector platform technology to deliver a corrected version of the MYO7A gene to address the vision loss associated with the disease. The Phase I/IIa